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Abstract
Introduction MicroRNAs (miRNAs) are a class of small
noncoding RNAs that control gene expression by targeting
mRNAs and triggering either translation repression or RNA
degradation. Their aberrant expression may be involved in
human diseases, including cancer. To test the hypothesis that
there is a specific miRNA expression signature which
characterizes male breast cancers, we performed miRNA
microarray analysis in a series of male breast cancers and
compared them with cases of male gynecomastia and female
breast cancers.
Methods Paraffin blocks were obtained at the Department of
Pathology of Thomas Jefferson University from 28 male patients
including 23 breast cancers and five cases of male
gynecomastia, and from 10 female ductal breast carcinomas.
The RNA harvested was hybridized to miRNA microarrays
(~1,100 miRNA probes, including 326 human and 249 mouse
miRNA genes, spotted in duplicate). To further support the
microarray data, an immunohistochemical analysis for two
specific miRNA gene targets (HOXD10  and  VEGF) was
performed in a small series of male breast carcinoma and
gynecomastia samples.
Results We identified a male breast cancer miRNA signature
composed of a large portion of underexpressed miRNAs. In
particular, 17 miRNAs with increased expression and 26
miRNAs with decreased expression were identified in male
breast cancer compared with gynecomastia. Among these
miRNAs, some had well-characterized cancer development
association and some showed a deregulation in cancer
specimens similar to the one previously observed in the
published signatures of female breast cancer. Comparing male
with female breast cancer miRNA expression signatures, 17
significantly deregulated miRNAs were observed (four
overexpressed and 13 underexpressed in male breast cancers).
The  HOXD10  and  VEGF  gene immunohistochemical
expression significantly follows the corresponding miRNA
deregulation.
Conclusions Our results suggest that specific miRNAs may be
directly involved in male breast cancer development and that
they may represent a novel diagnostic tool in the
characterization of specific cancer gene targets.
Introduction
Breast cancer is a rare disease in men, representing less than
1% of all malignancies and responsible for 0.1% of male can-
cer deaths [1,2]. Despite its infrequent prevalence, male
breast cancer can cause significant morbidity and mortality. In
fact, it has a more aggressive clinical behavior compared with
female breast cancer [2]. Most of the current knowledge
regarding male breast cancer biology, natural history and treat-
ment strategies is still limited and has been extrapolated from
its female counterpart.
HOXD10: homeobox-D10; IHC: immunohistochemical; miRNA: microRNA; PCR: polymerase chain reaction; VEGF: vascular endothelial growth fac-
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Genome-wide microarray gene expression analysis has been
largely used to characterize human cancers. This approach
allowed the identification of genes important in tumorigenesis.
Microarray tools have been recently enriched by the develop-
ment of platforms for the analysis of microRNA (miRNA)
expression [3,4]. miRNAs are ~22-nucleotide small noncod-
ing RNAs that modulate gene expression by binding to target
mRNA by imperfect complementary, causing either mRNA
degradation or translation inhibition [5]. In humans, aberrant
expression of miRNAs contributes to carcinogenesis by pro-
moting the expression of proto-oncogenes or by inhibiting the
expression of tumor suppressor genes. Such oncomirs have
been demonstrated in a variety of hematologic and solid malig-
nancies [6-8], and also in female breast cancer [9-31]. Fur-
thermore, interfering with miRNA expression, an altered
experimental tumorigenesis has been observed [14,32].
Indeed, genome-wide profiling integrated by functional studies
that involve overexpression and downregulation of miRNAs
represents the current approach that is most likely to yield
advances in the new field of noncoding RNA research. More-
over, miRNAs are, in contrast to most mRNAs, long-lived in
vivo and very stable in vitro, which might be critical in a clinical
setting and may allow analysis of paraffin-embedded samples
[11].
Previous studies have demonstrated that there is a large
number of deregulated miRNAs in human breast cancer (in
particular, miR-10b, miR-17-5p, miR-21, miR-27a, miR-27b,
miR-125a, miR-125b, miR-126, miR-145, miR-155, miR-
200c, miR-206, miR-336 and the let-7 family) [9-31]. The
miRNA signatures have been correlated with clinicopatholog-
ical and prognostic parameters such as tumor size, nodal
involvement, vascular invasiveness, ErbB2, estrogen receptor
status and chemotherapy resistance [9-11,13,21-
24,27,28,30,31]. Moreover, a functional polymorphism in the
miR-146a gene has been correlated with the predisposition to
an earlier age of onset of familial breast and ovarian cancers
[26]. Three recent studies proved the involvement of miRNAs
in breast cancer metastases [14,32,33]. For instance, miR-
10b overexpression leads to tumor invasion and metastasis by
suppressing HOXD10 and indirectly activating the prometa-
static gene RHOC [14]. Two other miRNAs (miR-373 and
miR-520c) can also promote tumor invasion and metastasis, at
least in part by regulating the CD44 gene [32]. In addition,
miR-335, miR-206 and miR-126 have been identified as sup-
pressors of breast cancer metastasis [33].
These findings strongly suggest that miRNA expression pro-
files could represent a promising new class of cancer biomar-
kers. Moreover, in the future, miRNAs could be potentially
used as innovative and targeted therapeutics [34].
In the present report we analyze the genome-wide miRNA
expression profile of 23 male breast carcinoma cases versus
five male gynecomastia cases, and of 10 female breast carci-
noma samples. Our data indicate a miRNA signature associ-
ated with male breast carcinoma and suggest miRNA
deregulation as an important event in male breast cell transfor-
mation.
Materials and methods
Tissue samples
After exempt status for the study was granted by the Institu-
tional Review Board of Thomas Jefferson University, speci-
mens from 28 male patients, including 23 cases of breast
cancer and five cases of gynecomastia, and from 10 female
patients affected by ductal breast carcinoma were identified
from the archival files of the Department of Pathology of Tho-
mas Jefferson University (Philadelphia, PA, USA). The patients
had undergone treatment by either simple mastectomy or wide
local excision and radiotherapy. Adjuvant therapy was not
given. All cases were reviewed by two pathologists (JPP and
RB) and the diagnoses confirmed. Four 15 μm sections were
obtained from each case.
For the immunohistochemical study, formalin-fixed and paraf-
fin-embedded tissues of 10 cases of male ductal breast carci-
noma and five cases of gynecomastia were obtained from the
archival files of the Department of Surgical Pathology of the
University of Padova.
All patients considered in this study gave their written informed
consent. The male breast cancer samples have been consid-
ered in an earlier publication [35].
MicroRNA microarray
Tissue sections were deparaffinized with xylene at 50°C for 3
minutes. Total RNA extraction was undertaken using the
RecoverAll kit (Ambion Inc, Austin, TX, USA) according to the
manufacturer's instructions. RNA labeling and hybridization on
miRNA microarray chips were performed as previously
described [36]. Briefly, 5 μg total RNA from each sample were
reverse-transcribed using biotin end-labeled random-octamer
oligonucleotide primer. Hybridization of biotin-labeled comple-
mentary DNA was performed on a new Ohio State University
custom miRNA microarray chip (OSU_CCC version 4.0),
which contains ~1,100 miRNA probes – including 326 human
and 249 mouse miRNA genes, spotted in duplicate [3]. The
hybridized chips were washed and processed to detect biotin-
containing transcripts by streptavidin- Alexa647 conjugate
and were scanned on an Axon 4000B microarray scanner
(Axon Instruments, Sunnyvale, CA, USA).
Statistical and bioinformatics analysis
Microarray images were analyzed using GENEPIX PRO 6.0
(Axon Instruments). Average values of the replicate spots of
each miRNA were background subtracted, normalized and fur-
ther analyzed. Normalization was performed using quantiles
[3]. The microarray data have been deposited at the NationalAvailable online http://breast-cancer-research.com/content/11/4/R58
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Center for Biotechnology Information Gene Expression Omni-
bus repository [GEO:GSE17155].
miRNAs that are differentially expressed between breast can-
cer and gynecomastia were identified using a random-variance
t test. The random-variance t test is an improvement over the
standard separate t  test as it permits sharing information
among genes about within-class variation without assuming
that all genes have the same variance [37]. Genes were con-
sidered statistically significant if their P value was less than
0.01. A stringent significance threshold was used to limit the
number of false positive findings [38]. Only mature miRNAs
that are differentially expressed are reported.
Our samples were not microdissected so, to further avoid the
influence of heterogeneity/a different percentage of cell types
between compared samples (cancer cells versus surrounding
stromal tissue cells), we performed an enrichment analysis for
the gynecomastia versus male breast cancer groups. The
enrichment analysis was performed by enriching the original
microarray analysis data for tumor area. For this purpose, the
tumor area – defined as the percentage of tumor over the stro-
mal counterpart – was histologically determined by two pathol-
ogists (JPP and RB).
Quantitative real-time PCR
The single-tube TaqMan miRNA Assay (Applied Biosystems,
Foster City, CA, USA) was used to detect and quantify mature
miRNAs on Applied Biosystems real-time PCR instruments in
accordance with the manufacturer's instructions. Normaliza-
tion was performed with the small nuclear RNA U48 (RNU48;
Applied Biosystems). All real-time reactions, including no-tem-
plate controls and real-time minus controls, were run in a
GeneAmp PCR 9700 thermocycler (Applied Biosystems).
Gene expression levels were quantified using the ABI Prism
7900HT Sequence Detection System (Applied Biosystems).
Comparative real-time PCR was performed in triplicate, includ-
ing no-template controls. The fold difference for each sample
was obtained using the expression 2-ΔCt, in which Ct is the
threshold cycle (the threshold cycle is the cycle number at
which the fluorescence generated within a reaction crosses
the threshold) and ΔCt is the difference between the average
Ct value of a sample gene and the average Ct for the endog-
enous reference RNU48. Total RNA from 19 of the 23 male
breast cancers and from the five gynecomastia samples were
used in the quantitative real-time PCR analysis. The RNA was
extracted from different tissue blocks to those used in the
miRNA microarray study.
Immunohistochemistry
Staining was performed automatically (Ventana Benchmark
XT system; Ventana Medical Systems, Touchstone, AZ, USA)
for vascular endothelial growth factor (VEGF) (catalog number
sc-152 – VEGF-A20, 1:100; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) and homeobox-D10 (HOXD10) (cata-
log number sc-66926, 1:50; Santa Cruz Biotechnology Inc.)
according to the manufacturer's instructions. Sections were
then lightly counterstained with hematoxylin. Appropriate pos-
itive and negative controls were run concurrently. The expres-
sion of each immunohistochemical (IHC) marker was jointly
scored by two pathologists (MF and MR). Cytoplasmic positiv-
ity was considered for VEGF, and both cytoplasmic and mem-
branous positivity were considered for HOXD10. Regarding
the IHC score intensity, positive staining was semi-quantified
with a three-tier system: negative positivity, low-grade positiv-
ity, high-grade positivity. Results were reported as positive
when staining was observed in at least 5% of the tumor cells.
When the staining intensity was heterogeneous, the highest
result was retained for scoring.
Results
MicroRNA expression signatures discriminate between 
gynecomastia and cancer and between male and female 
breast cancers
To identify deregulated miRNAs in male breast cancers, the
miRNA expression profiles were determined for five male
gynecomastia samples, 23 male breast cancer samples and
10 female breast cancer samples using a custom microarray
platform proven to give robust results, as validated by several
studies [3,4,10,12]. All of the 23 male breast cancer samples
pathologically corresponded to invasive ductal breast carci-
noma. The clinicopathological characteristics are summarized
in Table 1.
Comparison analysis showed the differential expression of
several miRNA genes between gynecomastia and male breast
c a n c e r .  I n  d e t a i l ,  w e  i d e n t i f i e d  1 7  m i R N A s  w i t h  i n c r e a s e d
expression and 26 miRNAs with decreased expression in male
breast cancer samples in comparison with gynecomastia sam-
ples (Table 2).
Although our samples were partially microdissected, contami-
nation by surrounding stromal cells was unavoidable. We
therefore performed an enriched analysis for the tumor area
(Table 3). miR-499-3p and miR-330-5p miRNA follow the
enrichment, decreasing in the gynecomastia and increasing in
the male breast cancer samples.
No significant association has been observed between clin-
icopathological tumor characteristics and miRNA gene
expression.
In the search for male/female breast cancer specific miRNAs,
we correlated male breast cancer with female breast cancer
miRNA gene expression profiles. This sex-specific comparison
showed a different expression of 17 miRNAs between the two
categories, with four upregulated and 13 downregulated miR-
NAs in male breast cancers (Table 4 and Figure 1).Breast Cancer Research    Vol 11 No 4    Fassan et al.
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Table 1
Clinicopathological characteristics of the 23 male breast cancer samples
Characteristic Value
Age 71.2 ± 9.0 (72.0)
Tumor size 20.0 ± 9.6 (20.0)
Diagnosis
Invasive ductal carcinoma 11 (47.8%)
Invasive ductal carcinoma + ductal carcinoma in situ 12 (52.2%)
Nuclear grade
I 3 (13.0%)
II 11 (47.8%)
III 9 (39.1%)
Histological grade
I 2 (8.7%)
II 12 (52.2%)
III 9 (39.1%)
Cytokeratin 5/6
0 19 (82.6%)
+ 1 (4.3%)
++ 3 (13.0%)
+++ 0 (0.0%)
Cytokeratin 14
0 19 (82.6%)
+ 2 (8.7%)
++ 0 (0.0%)
+++ 2 (8.7%)
Cytokeratin 18
0 1 (4.3%)
+ 0 (0.0%)
++ 3 (13.0%)
+++ 19 (82.6%)
pT
1 13 (56.5%)
2 10 (43.5%)
pN
0 8 (34.8%)
1 8 (34.8%)
2 1 (4.3%)
x 6 (26.1%)
pM
0 8 (34.8%)
1 2 (8.7%)
x 13 (56.5%)
Estrogen receptors
Positive 12 (95.7%)
Negative 1 (4.3%)
Not available 10
Progesterone receptors
Positive 13 (100.0%)
Negative 0 (0.0%)
Not available 10
Data presented as the mean ± standard deviation (median) or as n (%). -, negative; +, < 25%; ++, 25 to 50%; and +++, > 50%.Available online http://breast-cancer-research.com/content/11/4/R58
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Table 2
MicroRNA differential expression between male breast cancers and cases of male gynecomastia
MicroRNA Cancer normalized Gynecomastia normalized Fold changea P value
hsa-miR-26a-2 82.5 15.4 5.357 0.002517
hsa-miR-26b 137.7 27.2 5.062 0.006413
hsa-miR-499-3p 290.6 63.9 4.548 0.005332
hsa-miR-607 389.4 87 4.476 0.001533
hsa-miR-135b 199.3 45.7 4.361 0.008074
hsa-miR-616 269.9 66 4.089 0.008253
hsa-miR-769-5p 184.4 53.6 3.44 0.006534
hsa-miR-330-5p 291.1 89.2 3.263 0.001353
hsa-miR-132 155.7 49.2 3.165 0.007551
hsa-miR-149 461.7 161.6 2.857 0.003765
hsa-miR-557 686.1 286.4 2.396 0.005408
hsa-miR-29b-2 1,273.7 604.9 2.106 1.12 × 10-5
hsa-miR-657 2,499.3 1,277.2 1.957 0.000899
hsa-miR-483-3p 18,985.9 10,525.1 1.804 0.001411
hsa-miR-371-3p 9,741.4 5,642.1 1.727 0.003106
hsa-miR-593 1,805.1 1,051.3 1.717 0.001461
hsa-miR-596 1,430.8 909.5 1.573 0.000370
hsa-miR-92a 6,490.7 11,614.8 - 1.789 0.008752
hsa-miR-145 1,561.5 3,649.3 - 2.336 0.000110
hsa-miR-99b 678.8 1,697.8 - 2.500 0.000985
hsa-miR-214 1,392.7 3,717.6 - 2.667 4.31 × 10-5
hsa-miR-191 1,337.8 4,112 - 3.077 0.003671
hsa-miR-454 11.2 36.2 - 3.236 0.006250
hsa-miR-10a 1,765.9 5,748.8 - 3.257 5 × 10-6
hsa-miR-195 188.2 865.9 - 4.608 0.008269
hsa-miR-10b 13.4 84.9 - 6.329 0.000451
hsa-miR-130a 451.8 2,868.5 - 6.329 0.003837
hsa-miR-374a 18.1 128.8 - 7.092 0.000556
hsa-miR-146b-5p 190.4 1,459.9 - 7.692 0.005392
hsa-miR-146a 129.2 1,070.7 - 8.264 0.007859
hsa-miR-181c 63.9 539.1 - 8.403 0.001424
hsa-miR-218 10 99.7 - 10.000 3 × 10-7
hsa-let-7g 59 611.5 - 10.417 0.002014
hsa-miR-15b 21.5 229.2 - 10.638 0.001555
hsa-miR-125a-5p 62.5 790.1 - 12.658 0.001136
hsa-miR-223 79.8 1,158.8 - 14.493 0.000837
hsa-miR-99a 70 1,111.4 - 15.873 0.000261
hsa-miR-140-3p 18.1 291.8 - 16.129 2.31 × 10-5
hsa-miR-126 16.7 2,71.9 - 16.393 5.67 × 10-5
hsa-miR-199b-3p 136 2,517.8 - 18.519 0.003903
hsa-miR-100 84.9 1,757.3 - 20.833 0.000104
hsa-miR-199a-5p 35.3 782.6 - 22.222 0.000256
hsa-miR-125b 95.3 2,992.6 - 31.250 9.91 × 10-5
aPresented as the actual change in expression.Breast Cancer Research    Vol 11 No 4    Fassan et al.
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Quantitative real-time PCR analysis
To confirm the results of microarray analysis, we performed
quantitative real-time PCR analysis on a limited number of
samples (19 cancer samples, five gynecomastia samples)
using probes corresponding to miR-125b, miR-126, miR-10b,
miR-10a, miR-191, miR-26b, miR-607 and miR-135b (Figure
2). The quantitative real-time PCR analysis confirmed the
results obtained by microarray analysis. In fact, miR-125b,
miR-126, miR-10b, miR-10a and miR-191 were underex-
pressed whereas miR-26b, miR-607 and miR-135b were
overexpressed in cancer samples examined, in comparison
with the gynecomastia samples.
Immunohistochemical analysis
To further confirm our microarray data, and to demonstrate
that miRNA analysis may be important in investigations into
male breast cancer specific genes, we sought to correlate the
expression of significantly deregulated miRNA genes in male
breast cancer samples with two of their previously reported
targets (Figure 3a). For this purpose, we performed an IHC
analysis on the HOXD10 and VEGF genes [14,39].
The  HOXD10  gene represses the expression of genes
involved in cell migration and extracellular matrix remodeling in
breast cancer cells, and it is regulated by miR-10b [14]. Since
we observed miR-10b to be downregulated in male breast
cancers, we therefore decided to analyze HOXD10 expres-
sion in formalin-fixed paraffin-embedded tissue samples
Table 3
MicroRNA differential expression between male breast cancers and male gynecomastia after enrichment for tumor cellularity
MicroRNA Cancer normalized Gynecomastia normalized Fold changea P value
hsa-miR-499-3p 300.2 17.7 16.96 0.000361
hsa-miR-129-3p 124.3 10.0 12.43 0.001482
hsa-miR-330-5p 322.1 66.6 4.836 0.003715
hsa-miR-10a 1829.8 6683.6 - 3.650 0.000353
hsa-miR-191 1655.3 6552.6 - 3.952 0.007160
hsa-miR-338-5p 17.3 106.7 - 6.173 0.005437
hsa-miR-218 10.0 74.6 - 7.463 0.000527
hsa-miR-369-3p 17.5 151.8 - 8.674 0.002524
hsa-miR-454 11.8 102.8 - 8.711 0.000753
hsa-miR-10b 15.1 132.8 - 8.772 0.005204
hsa-miR-374a 17.6 238.3 - 13.514 0.000447
hsa-miR-126 18.8 315.2 - 16.667 0.003277
hsa-miR-140-3p 18.6 340.7 - 18.182 0.000843
aPresented as the actual change in expression.
Figure 1
MicroRNA differential expression in male versus female breast cancers MicroRNA differential expression in male versus female breast cancers. Hierarchical clustering of the 17 microRNA genes with a significantly differ-
ent expression. Rows, individual genes; columns, individual tissue samples. Pseudocolors indicate transcript levels below, equal to, or above the 
mean (green, black, and red, respectively). The scale represents the intensity of gene expression (log2 scale ranges between -3 and 3).Available online http://breast-cancer-research.com/content/11/4/R58
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obtained from 10 male breast cancer patients and five gyne-
comastia patients. As expected, the five gynecomastia sam-
ples showed a weak cytoplasmic HOXD10 IHC positivity,
whereas 8/10 male breast cancers samples showed
HOXD10 moderate- strong cytoplasmic positivity with mem-
branous reinforcement (Figure 3b to 3d).
VEGF is a positive regulator of angiogenesis, and its expres-
sion is upregulated in many types of cancers, including breast
cancers. VEGF is also a target protein of miR-126 [39]. Given
the downregulation of miR-126 in male breast cancers, we
tested VEGF IHC expression in our series of male breast can-
cers/gynecomastia. In gynecomastia samples VEGF showed
weak cytoplasmic immunoreactions, whereas in 9/10 males a
strong cytoplasmic reactivity was observed (Figure 3e to 3g).
Discussion
Aberrant miRNA expression patterns have been described in
a variety of hematologic and solid-organ malignancies, and
several miRNA signatures have also been described for female
breast cancer [10-30]. In the present study we have identified
a global expression pattern of miRNAs that can differentiate
gynecomastia from male breast cancer and can differentiate
male breast cancer from female cancers.
Table 4
MicroRNA differential expression between male and female breast cancers
MicroRNA Male normalized Female normalized Fold changea P value
hsa-miR-663 492.9 77.5 6.369 7.1 × 10-6
hsa-miR-618 428.3 106.7 4.444 2.0 × 10-7
hsa-miR-605 174.0 44.4 3.922 0.000373
hsa-miR-616 309.2 86.0 3.597 0.000213
hsa-miR-200b 147.6 642.8 - 4.354 0.000144
hsa-miR-181c 145.9 656.1 - 4.500 0.000624
hsa-miR-106a 199.3 914.7 - 4.589 0.000594
hsa-miR-125a-5p 131.0 697.9 - 5.326 0.000698
hsa-miR-16 351.6 2021.7 - 5.750 0.000871
hsa-miR-25 309.3 1875.1 - 6.062 0.000992
hsa-miR-100 196.8 1206.9 - 6.132 0.000160
has-let-7f 39.0 241.4 - 6.186 0.000380
hsa-miR-125b 206.6 1427.7 - 6.912 0.000513
hsa-miR-15b 48.7 364.5 - 7.108 0.000508
hsa-miR-425 53.5 436.3 - 8.161 0.000614
hsa-miR-199a-5p 84.7 710.0 - 8.387 0.000306
hsa-miR-223 167.3 1414.6 - 8.454 0.000111
aPresented as the actual change in expression.
Figure 2
Quantitative real-time PCR validation of microRNA microarray results in  male breast cancers Quantitative real-time PCR validation of microRNA microarray results in 
male breast cancers. Relative expression of microRNAs in male breast 
cancer compared with cases of gynecomastia by real-time PCR. miR-
125b, miR-126, miR-10b, miR-10a and miR-191 were underexpressed 
in cancer samples, whereas miR-26b, miR-607 and miR-135b were 
overexpressed. Dots, normalized ratio microRNA gene expression val-
ues (breast cancers/gynecomastia); error bars, standard deviation.Breast Cancer Research    Vol 11 No 4    Fassan et al.
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Gynecomastia is the most common clinical and pathologic
abnormality of the male breast. It results from hypertrophy of
breast tissue. Numerous conditions have been associated
with gynecomastia, but the pathophysiological bases are due
to an imbalance of sex hormones and the tissue responsive-
ness to them.
Previous studies of miRNA expression in human breast cancer
have focused on comparing normal tissues with tumor sam-
ples [10,11,21]. Because of the absence in men of a normal
nonhypertrophic breast gland, we choose to compare gyneco-
mastia with male breast cancer. In fact, gynecomastia has a
higher amount of breast epithelium than normal breast. Gyne-
comastia could therefore be considered a good normal control
for male breast cancer.
We identified a miRNA signature for male breast cancer, com-
posed of 43 miRNAs that were differently expressed between
tumors and gynecomastia samples. In particular, 17 miRNAs
were upregulated and 26 miRNAs were downregulated in
cancers (Table 2). Interestingly, in this signature we identified
miRNAs that had previously been associated with breast can-
cers compared with normal tissues. Two overexpressed miR-
NAs – miR-149 [10] and miR-29b [12,21,22] – have already
been described as upregulated in other female breast cancer
studies. On the other hand, miR-145 [10,20], miR-10b [10],
let-7g [19], miR-125a-5p [10,31], miR-125b [31] and miR-
126 [40] have been described as downregulated.
According to previous reports in female breast carcinogene-
sis, the most interesting and promising miRNAs of this male
breast cancer signature are miR-10b, miR-126, miR-125a-5p
and miR-125b [14,31,40].
miR-10b has been previously described as downregulated in
female breast cancer compared with normal tissue [10], but it
has been also associated with the induction of tumor invasion
and metastasis of breast cancer derived cells by targeting
HOXD10 [14]. The downregulation of HOXD10 permits sub-
sequently the expression of the prometastatic gene product
RHOC, favoring, in turn, cancer cell migration and invasion
[14]. Gee and colleagues, however, showed that miR-10b is
not significantly associated with breast cancer metastasis in a
large series of early-stage breast cancers [41].
We observed in our tumor samples a downregulation of miR-
125a-5p, miR-125b, miR-126, miR-145 and let-7g genes,
which have been shown to be related to hormonal settings and
Figure 3
miR-10b and miR126 genes are downregulated in male breast cancers versus gynecomastia miR-10b and miR126 genes are downregulated in male breast cancers versus gynecomastia. (a) Columns represent individual tissue samples. 
Pseudocolors indicate transcript levels below, equal to, or above the mean (green, black, and red, respectively). The scale represents the intensity of 
gene expression (log2 scale ranges between -3 and 3). Representative examples of (b), (c), (d) homeobox-D10 and (e), (f), (g) vascular endothelial 
growth factor immunohistochemical expression in male breast cancers and gynecomastia samples. (b) and (e) Weak immunohistochemical staining 
in gynecomastia samples. (c), (d), (f) and (g) Positive immunoreactions in male breast cancer samples.Available online http://breast-cancer-research.com/content/11/4/R58
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ErbB2 status of the tumor: miR-125a-5p and miR-125b down-
regulate ErbB2 and ErbB3 expression [31], miR-126 and let-
7g are upregulated in ErbB2-negative tumors, whereas miR-
145 is upregulated in ErbB2-negative tumors and upregulated
in estrogen-receptor-positive and progesterone-receptor-pos-
itive tumors [13].
Our IHC study supports previous reports on the relationship of
miR-10b and miR-126 and their respective gene targets
[14,39]. Larger prospective studies are needed to confirm our
IHC data, but we have further suggested that miRNA profiling
may be helpful in the discovery of new breast cancer gene tar-
gets.
Although our tumor samples were partially microdissected,
contamination with surrounding stromal tissue is inevitable.
For this reason we performed an enrichment analysis of our
data considering the amount of tumor tissue analyzed (Table
3). In this analysis, we observed that two miRNAs – miR-499-
3p and miR-330-5p – were upregulated in cancer samples
and followed the enrichment, suggesting they are key miRNAs
in male breast cancer. Because these two miRNAs have not
yet been associated with cancer development, we are plan-
ning to test their possible role in breast cell transformation with
functional studies. Other miRNAs similarly altered after the
enrichment, such as miR-191, miR-454, miR-10a, miR-374a,
miR-10b, miR-218, miR-140-3p and miR-126, were downreg-
ulated in cancer. This group of miRNAs could also be impor-
tant in the transformation of male breast cells. On the other
hand, one could question whether these miRNAs are basically
expressed in normal stromal cells and the enrichment is only a
secondary effect to the loss of the stromal counterpart.
Of interest, from a histological point of view, male breast can-
cer is usually an invasive ductal carcinoma [35]. This histotype
specificity seems one of the major differences between male
and female breast cancer biology. We therefore analyzed the
miRNA expression profiles of male/female breast cancer sam-
ples, looking for miRNAs differentially expressed between the
two clinical categories. We identified 17 deregulated miRNAs
(Table 4). Further studies considering large series of male/
female breast tumors need to be conducted to address a pos-
sible role of miRNAs concerning the biological and prognostic
tumor characteristics.
Conclusions
The present report provides the first study on miRNA expres-
sion in male breast cancer. Considering gynecomastia as a
potentially benign counterpart of male breast glands, we iden-
tified miRNAs that are differentially expressed between cancer
and gynecomastia. Moreover, we investigated the differences
between miRNA gene expression profiles in male versus
female breast cancers.
The functional significance of miRNA dysregulation we have
shown needs to be further investigated. Our results suggest
that specific miRNAs may be directly involved in male breast
cancer development and that they may represent a novel diag-
nostic tool in the characterization of specific cancer gene tar-
gets.
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